Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Dermatologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Optimal management of skin cancer in immunosuppressed patients.Am J Clin Dermatol. 2014; 15: 339-356
- Lymphoma-associated skin cancer: incidence, natural history, and clinical management.Int J Dermatol. 2014; 53: 267-274
- Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic leukemia and solid-organ transplantation.Dermatol Surg. 2003; 29: 129-134
- High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia.Dermatol Surg. 2005; 31 ([discussion: 42]): 38-42
- Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.JAMA Dermatol. 2014; 150: 280-287
- HPV Carcinomas in Immunocompromised Patients.J Clin Med. 2015; 4: 260-281
- Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load.JAMA Dermatol. 2017; 153: 892-896
- Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in hiv-positive men who have sex with men.Clin Infect Dis. 2015; 61: 1527-1535
- HIV-associated cancers and related diseases.N Engl J Med. 2018; 378: 1029-1041
- Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients.J Am Acad Dermatol. 2011; 65: 253-261
- Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients.J Am Acad Dermatol. 2011; 65: 263-279
- Skin cancers after organ transplantation.N Engl J Med. 2003; 348: 1681-1691
- Risk of merkel cell carcinoma after solid organ transplantation.J Natl Cancer Inst. 2015; 107
- Squamous cell skin cancer (Version 2.2021.(Available at:) (Accessed November 10, 2021)
- Basal cell skin cancer (Version 2.2021.(Available at:) (Accessed November 10, 2021)
- Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines.Transpl Int. 2019; 32: 1268-1276
- Association of pretransplant skin cancer with posttransplant malignancy, graft failure and death in kidney transplant recipients.Transplantation. 2017; 101: 1303-1309
- Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.Am J Transplant. 2021; 21: 475-483
- Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients: a delphi consensus statement.JAMA Dermatol. 2021; 157: 1219-1226
- Melanoma risk and survival among organ transplant recipients.J Invest Dermatol. 2015; 135: 2657-2665
- Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis.Arch Dermatol. 2011; 147: 790-796
- Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.Br J Dermatol. 2009; 161: 78-84
- Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines.Am J Transpl. 2017; 17: 103-114
- Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study.Transpl Int. 2019; 32: 1259-1267
- Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey.Br J Dermatol. 2006; 154: 395-400
- Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results.J Clin Oncol. 2018; 36: 2612-2620
- Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.BMJ. 2014; 349: g6679
- Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort.Am J Transpl. 2016; 16: 565-573
- Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer.JAMA Dermatol. 2016; 152: 164-172
- Non-melanoma skin cancers and glucocorticoid therapy.Br J Cancer. 2001; 85: 683-686
- Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.Leukemia. 2019; 33: 1996-2005
- Systemic medications linked to an increased risk for skin malignancy.Cutis. 2019; 104: E32-E36
- Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States.JAMA Dermatol. 2020; 156: 772-779
- Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses.J Am Acad Dermatol. 2021; 84: 528-530
- Skin Cancers in Organ Transplant Recipients.Am J Transpl. 2017; 17: 2509-2530
- Capecitabine for squamous cell carcinoma reduction in solid organ transplant recipients.JAAD Case Rep. 2015; 1: S16-S18
- Emerging concepts and recent advances in basal cell carcinoma.F1000Res. 2017; 6: 2085
- Performance of the american joint committee on cancer staging manual, 8th edition vs the brigham and women's hospital tumor classification system for cutaneous squamous cell carcinoma.JAMA Dermatol. 2019; 155: 819-825
- The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.CA Cancer J Clin. 2017; 67: 93-99
- Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.JAMA Dermatol. 2013; 149: 402-410
- TNM classification of malignant tumours.John Wiley & Sons, Oxford, UK2011
- Brigham and Women's Hospital tumor classification system for basal cell carcinoma identifies patients with risk of metastasis and death.J Am Acad Dermatol. 2021; 85: 582-587
- AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.Dermatol Surg. 2012; 38: 1582-1603
- Evaluation of watchful waiting and tumor behavior in patients with basal cell carcinoma: an observational cohort study of 280 basal cell carcinomas in 89 patients.JAMA Dermatol. 2021; 157: 1174-1181
- Skin cancer precursor immunotherapy for squamous cell carcinoma prevention.JCI Insight. 2019; 4: e125476
- Rate of regional nodal metastases of cutaneous squamous cell carcinoma in the immunosuppressed patient.Am J Otolaryngol. 2017; 38: 325-328
- The positive impact of radiologic imaging on high-stage cutaneous squamous cell carcinoma management.J Am Acad Dermatol. 2017; 76: 217-225
- Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma.Curr Oncol. 2020; 27: e399-e407
- A Systematic review of primary, adjuvant, and salvage radiation therapy for cutaneous squamous cell carcinoma.Dermatol Surg. 2021; 47: 587-592
- A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.Cancer. 2017; 123: 2054-2060
- Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.Ann Oncol. 2021; 32: 1276-1285
- PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.N Engl J Med. 2018; 379: 341-351
- Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.J Clin Oncol. 2011; 29: 3419-3426
- Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.J Heart Lung Transpl. 2007; 26: 1340-1344
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.Lancet Oncol. 2021; 22: 848-857
- Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.Future Oncol. 2021; 17: 611-627
- Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial.J Clin Oncol. 2018; 36: 1275-1283
- Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review.Am J Transpl. 2020; 20: 2457-2465
- Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review.JAMA Oncol. 2019; 5: 1049-1054
- Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.J Immunother Cancer. 2020; 8
- Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review.J Am Acad Dermatol. 2020; 82: 1490-1500
- Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.JAMA Dermatol. 2015; 151: 70-72
- The rule of 10s versus the rule of 2s: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas.J Am Acad Dermatol. 2021; 85: 442-452
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med. 2012; 367: 1694-1703
- Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.Br J Dermatol. 2019; 181: 186-189
- Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies.J Am Acad Dermatol. 2018; 78: 184-185
- Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage.J Invest Dermatol. 2013; 133: 642-646
- Merkel cell carcinoma and HIV infection.Lancet. 2002; 359: 497-498
- Merkel Cell Carcinoma (Version 2.2021.(Available at:) (Accessed November 10, 2021)
- Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.Cancer. 2017; 123: 1464-1474
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.J Clin Oncol. 2019; 37: 693-702
- Kaposi sarcoma.Nat Rev Dis Primers. 2019; 5: 9
- Outcome of kidney transplant recipients with previous human herpesvirus-8 infection.Transplantation. 2000; 69: 1776-1779
- Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients.N Engl J Med. 1998; 339: 1358-1363
- Sirolimus for Kaposi's sarcoma in renal-transplant recipients.N Engl J Med. 2005; 352: 1317-1323
- The previously common post-kidney transplant Kaposi sarcoma has become non-existent for a decade: an Egyptian experience.J Cancer Res Clin Oncol. 2021; 147: 1493-1498
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
